Expression of complement receptor type 1 (CR1) on erythrocytes of paracoccidiodomycosis patients

被引：5

作者：

Teixeira J.E. ^{[1
]}

Martinez R. ^{[2
]}

Câmara L.M.C. ^{[3
]}

Barbosa J.E. ^{[1
]}

机构：

[1] Department of Parasitology, Microbiology and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP

[2] Department of Internal Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP

[3] Federal University of Ceará, Fortaleza, CE

来源：

Mycopathologia | 2001年 / 152卷 / 3期

关键词：

CR1 (complement receptor type 1); CRP (C reactive protein); HAIgG (heat-aggregated human IgG); IC (immunocomplexes); PCM (paracoccidioidomycosis);

D O I：

10.1023/A:1013123721376

中图分类号：

学科分类号：

摘要：

Complement receptor type 1 (CR1) is a membrane glycoprotein that acts as a receptor for the C3b, iC3b and C4b fragments of complement. In primates, one function of erythrocytes is to promote safe clearance of immunocomplexes (IC) from the circulation through CR1. Theoretically, in diseases characterized by high levels of circulating IC, an erythrocyte CR1 (CR1/E) deficiency may favor IC deposition in tissues or facilitate inappropriate activation of leukocytes in the circulation. Depression of the cell immune response occurs in paracoccidioidomycosis (PCM), especially in the more severe cases, and is frequently associated with high serum IC levels. In the present study we quantified the number of CR1/E in patients with the acute and chronic forms of PCM before and after treatment and correlated it with serum IC levels and CD4+ and CD8+ T cell concentration in the peripheral blood of these patients. Patients with PCM, particularly those with active disease and who had received treatment for shorter periods of time, had low numbers of CR1/E. In addition, an increase in serum IC concentration and a reduction in the CD4+/CD8+ T cell ratio were observed. After treatment there was a significant increase in mean CR1/E number and a reduction in serum IC levels. In patients with the chronic form of the disease the CD4+/CD8+ T cell ratio tended to increase after treatment and was associated with increased CR1/E levels. These results suggest that the reduction in CR1/E observed in patients is a phenomenon acquired with the disease and that CR1 could play a role in the pathogenesis of PCM.

引用

页码：125 / 133

页数：8

共 47 条

[11]

Hebert L.A., The clearance of immune complexes from the circulation of man and other primates, Am J Kidney Dis, 17, pp. 352-361, (1991)

[12]

Schifferli J.A., Taylor R.P., Physiological and pathological aspects of circulating immune complex, Kidney Int, 35, pp. 993-1003, (1989)

[13]

Kanto T., Hayashi N., Takehara T., Katayama K., Kato M., Akiyama M., Kasahara A., Fusamoto H., Kamada T., Low expression of erythrocyte complement receptor type 1 in chronic hepatitis C patients, J Med Virol, 50, pp. 126-134, (1996)

[14]

Kumar A., Malaviya A.N., Srivastava L.M., Lowered expression of C3b receptor (CR1) on erythrocytes of rheumatoid arthritis patients, Immunobiology, 191, pp. 9-20, (1994)

[15]

Pascual M., Danielsson C., Steiger G., Schifferli J.A., Proteolytic cleavage of CR1 on human erythrocytes in vivo: Evidence for enhanced cleavage in AIDS, Eur J Immunol, 24, pp. 702-708, (1994)

[16]

Walport M.J., Lachmann P.J., Erythrocyte complement receptor type 1, immune complexes and the rheumatic diseases, Arthritis Rheum, 31, pp. 153-158, (1988)

[17]

Tausk F.A., Mccutchan A., Spechko P., Schreiber R.D., Gigli L., Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome, J Clin Invest, 78, pp. 977-982, (1986)

[18]

Green R.D., Webb D., Saying the 'S' word in public, Immunol Today, 14, pp. 523-525, (1993)

[19]

Seder R.A., Gros L.G., The functional role of CD8+ T helper type 2 cells, J Exp Med, 181, pp. 5-7, (1995)

[20]

Cerwenka A., Carter L.L., Reome J.B., Swain S.L., Dutton R.W., In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines, J Immunol, 161, pp. 97-105, (1998)

← 1 2 3 4 5 →